Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]

Corrigendum to ‘Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC’ [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828] The authors regret errors in the published data presented in Tables 1 and 3 of this article. In Table 1, the median number of lines of prior systemic therapy for advanced/metastatic disease in the T-DXd 6.4 mg/kg group was corrected from 1.7 to 2.0. In Table 3, the values for prior immuno-oncology therapy were corrected. In the T-DXd 5.4 mg/kg group, prior immunooncology therapy (Yes) was corrected from 10/15 (66.7%) to 11/15 (73.3%), and prior immuno-oncology therapy (No) was corrected from 5/15 (33.3%) to 4/15 (26.7%). In the T-DXd 6.4 mg/kg group, prior immuno-oncology therapy (Yes) was corrected from 12/16 (75.0%) to 13/16 (81.3%), and prior immuno-oncology therapy (No) was corrected from 4/16 (25.0%) to 3/16 (18.8%). In addition, the values for time from prior immuno-oncology therapy (>6 months) were corrected from 4/15 (26.7%) to 5/15 (33.3%) in the T-DXd 5.4 mg/kg group and from 6/16 (37.5%) to 7/16 (43.8%) in the T-DXd 6.4 mg/kg group. In Figure 2B, the number of patients censored at 20 months in the T-DXd 5.4 mg/kg group was corrected from 2 to 21. These corrections do not affect the results, interpretation, or conclusions of the study. The authors apologize for any inconvenience caused.